Liquidia Technologies Inc.
627 Davis Drive
59 articles with Liquidia Technologies Inc.
The U.S. Food and Drug Administration (FDA) has a busy end of November planned, with numerous PDUFA dates to address. Here’s a look at the upcoming week.
8/21/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
DLA Piper represented Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, in its acquisition of RareGen, LLC, a portfolio company of healthcare investment firm PBM Capital.
United Therapeutics Corporation announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. for infringement of the following patents relating to United Therapeutics' product Tyvaso® Inhalation Solution: U.S. Patent Nos. 9,604,901 and 9,593,066, both of which expire in December 2028.
Liquidia Technologies, Inc. announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors as a Class II director with a term expiring at the 2020 annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee.
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
• LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA • NDA submission targeted for late 2019
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
Liquidia Technologies, Inc. announced the closing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share for gross proceeds of $50.0 million before underwriting discounts and commissions.
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the pricing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions, for gross proceeds of $50.0 million.
Ms. Thomas will have responsibility for developing and leading Liquidia’s commercial plans, with initial focus on LIQ861, an inhaled dry powder formulation of treprostinil currently being evaluated in a pivotal Phase 3 safety trial for the treatment of pulmonary arterial hypertension.
Mr. Gordon will oversee finance operations and strategy, corporate development and legal functions.
Liquidia Presents Positive LIQ861 Results at the Annual World Congress of the Pulmonary Vascular Research Institute
Liquidia today announced positive Phase 1 and preclinical results evaluating LIQ861 for the treatment of PAH at the 12th Pulmonary Vascular Research Institute (PVRI) Annual World Congress on Pulmonary Vascular Disease in Singapore.
Liquidia Initiates Phase III Clinical Trial of LIQ861 in Patients with Pulmonary Arterial Hypertension
Liquidia announced the initiation of a Phase 3 clinical trial evaluating LIQ861 for the treatment of pulmonary arterial hypertension (PAH).
Liquidia Technologies Inc. Announces Positive Phase I Data For LIQ865, Sustained-Delivery PRINT Formulation Of Bupivacaine For Post-Surgical Pain Relief
Liquidia Technologies Inc. And GlaxoSmithKline Advance Existing Collaboration; GlaxoSmithKline Exercises Option For Inhaled Therapeutics